阿德福韦酯联合双环醇治疗慢性乙型肝炎患者临床观察

Clinical study on adefovir dipivoxil and bicyclol in treatment of patients with chronic hepatitis B

目的探讨阿德福韦酯联合双环醇治疗慢性乙型肝炎患者的疗效。方法 62例慢性乙型肝炎患者应用阿德福韦酯和双环醇治疗,60例患者仅应用阿德福韦酯治疗,观察96周。结果在治疗96周时,治疗组肝功能复常率为96.8%,对照组为80.0%(x2=5.8,P<0.01);两组HBeAg和HBV DNA阴转率比较差异无统计学意义(41.9%对33.3%,x2=2.1,P>0.05和85.5%对73.3%,x2=0.6,P>0.05);两组血清透明质酸、层粘连蛋白、Ⅲ型前胶原肽和Ⅳ型胶原比较差异有统计学意义(P<0.01);两组肝组织炎性活动度(t=4.1,P<0.01))和纤维化程度(t=3.2,P<0.01)变化的比较差异有统计学意义。结论阿德福韦酯联合双环醇治疗慢性乙型肝炎患者,随着肝功能的恢复,血清肝纤维化指标迅速降低。

Objective To explore adefovir dipivoxil and bicyclol in treating patients with chronic hepatitis B.Methods 62 patients with chronic hepatitis B were treated with adefovir dipivoxil and bicyclol for 96 weeks,and 60 were with adefovir dipivoxil for 96 weeks.Results At the end of the 96 week treatment,the ALT normalization rate in combination group was 96.8%,much higher than in control（80.0%,x2=5.8,P0.01）;the HBeAg（41.9% vs.33.3%,x2=2.1,P0.05）and HBV DNA loss（85.5% vs.73.3%,x2=0.6,P0.05）in the two groups were not significantly different;the serum HA,LN,PC Ⅲ and Ⅳ-C levels in combination group decreased more obviouly than in control（P0.01）.Conclusion Adefovir dipivoxil combined with bicyclol can improve liver function,and decrease serum markers of liver fibrosis.